Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lyrica Generics Were Likely Delayed By A Pfizer Labeling Supplement

Executive Summary

US FDA's last-minute approval may have allowed Pfizer three more weeks of sales without competition.

You may also be interested in...



Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes

A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.

Lyrica Generics Launch, But Pfizer Has Been Bracing For The Hit

The first generic versions of Pfizer's blockbuster pain medicine pregabalin have launched in the US. Pfizer has guided investors the company will return to growth in 2020 after cycling through the loss.

Lyrica Rivals Are Rolled Out In The US

Several generic rivals to Pfizer’s Lyrica have hit the US market following the anti-seizure and pain brand’s loss of exclusivity.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB140537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel